LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "mepolizumab" as a keyword



Effectiveness of mepolizumab in severe asthma in Japan: A real‐world study using claims data

Sign Up to like & get
recommendations! Published in 2021 at "Clinical and Translational Allergy"

DOI: 10.1002/clt2.12063

Abstract: To the Editor, Patients with severe eosinophilic asthma experience frequent exacerbations and may require oral corticosteroids (OCS) to maintain asthma control. In randomized controlled trials (RCTs), the anti‐interleukin‐5 monoclonal antibody, mepolizumab, reduces exacerbation rates and… read more here.

Keywords: study; index; treatment; mepolizumab ... See more keywords

La pharmacocinétique et la pharmacodynamie du mépolizumab chez les enfants âgés entre 6 et 11 ans avec un asthme sévère éosinophilique

Sign Up to like & get
recommendations! Published in 2019 at "Revue des Maladies Respiratoires"

DOI: 10.1016/j.rmr.2018.10.113

Abstract: Resume Introduction L’anticorps monoclonal anti-IL5 mepolizumab a ete approuve par l’UE, les Etats-Unis et d’autres marches internationaux comme traitement additionnel au traitement de fond chez les patients adultes avec un asthme severe eosinophilique (ASE). Dans plusieurs… read more here.

Keywords: ont recu; ans avec; chez les; avec asthme ... See more keywords

Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore

Sign Up to like & get
recommendations! Published in 2020 at "Journal of Asthma"

DOI: 10.1080/02770903.2020.1837158

Abstract: Abstract Objective To evaluate the cost-effectiveness of mepolizumab added to standard of care (SOC) compared with SOC alone among patients with severe uncontrolled eosinophilic asthma in the Singapore setting. Methods A Markov model with three… read more here.

Keywords: cost effectiveness; cost; care; mepolizumab ... See more keywords

Impact of mepolizumab in patients with high-burden severe asthma within a managed care population

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Asthma"

DOI: 10.1080/02770903.2022.2102036

Abstract: Abstract Objective To evaluate the real-world impact of mepolizumab on the incidence of asthma exacerbations, oral corticosteroid (OCS) use and asthma exacerbation-related costs in patients with high-burden severe asthma. Methods This was a retrospective study… read more here.

Keywords: patients high; asthma exacerbation; mepolizumab; exacerbation ... See more keywords

Achieving clinical remission in asthma with mepolizumab: a subanalysis on vitamin D as a predictor of response

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Asthma"

DOI: 10.1080/02770903.2024.2419435

Abstract: Abstract Objective Mepolizumab, an anti-IL-5 monoclonal antibody, has shown promise in reducing exacerbations and steroid dependency in severe eosinophilic asthma. This study aims to evaluate the effectiveness of mepolizumab in achieving clinical remission in asthma… read more here.

Keywords: mepolizumab; predictor response; vitamin; clinical remission ... See more keywords

Real-world effectiveness of mepolizumab in asthma: a systematic review and meta-analysis

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Asthma"

DOI: 10.1080/02770903.2024.2449229

Abstract: Abstract Objective Exacerbations and suboptimal disease control are common in severe asthma with an eosinophilic phenotype (SAep). Mepolizumab, an anti-interleukin-5 monoclonal antibody, has demonstrated efficacy and safety in randomized controlled trials (RCTs). We aimed to… read more here.

Keywords: rate; real world; meta analysis; mepolizumab ... See more keywords

A rare case of sudden blindness following mepolizumab withdrawal in EGPA

Sign Up to like & get
recommendations! Published in 2025 at "Current Medical Research and Opinion"

DOI: 10.1080/03007995.2025.2517693

Abstract: Abstract Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis primarily affecting individuals with asthma and hypereosinophilia. Among the available treatment options for EGPA, biological therapies such as Mepolizumab have emerged for controlling eosinophilic… read more here.

Keywords: treatment; mepolizumab; mepolizumab withdrawal; egpa ... See more keywords

An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma

Sign Up to like & get
recommendations! Published in 2025 at "Expert Opinion on Biological Therapy"

DOI: 10.1080/14712598.2025.2457779

Abstract: ABSTRACT Introduction Clinical experience with anti-interleukin (IL)-5 biologic therapies for severe asthma has been increasing, alongside deeper and broader research focusing on the role of IL-5 and the IL-5 targeted mepolizumab. This review aims to… read more here.

Keywords: eosinophilic asthma; treatment; mepolizumab; severe eosinophilic ... See more keywords

Drug evaluation: mepolizumab in chronic obstructive pulmonary disease.

Sign Up to like & get
recommendations! Published in 2025 at "Immunotherapy"

DOI: 10.1080/1750743x.2025.2504326

Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality globally, marked by persistent respiratory symptoms and exacerbations. It is now acknowledged to be a heterogeneous disease with respect to clinical expression and key… read more here.

Keywords: disease; drug evaluation; chronic obstructive; mepolizumab ... See more keywords

SP0119 The evolving role of mepolizumab in egpa

Sign Up to like & get
recommendations! Published in 2018 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2018-eular.7727

Abstract: There is overwhelming evidence that eosinophiles play a key role in the pathogenesis of EGPA. Il-5 is the central cytokine for eosinophil maturation, eosinophil release from the bone marrow and eosinophil survival. Mepolizumab is an… read more here.

Keywords: evolving role; mepolizumab; remission; mepolizumab egpa ... See more keywords

P134 Real world experience of mepolizumab in steroid-dependent severe eosinophilic asthma: one year outcomes

Sign Up to like & get
recommendations! Published in 2018 at "Thorax"

DOI: 10.1136/thorax-2018-212555.292

Abstract: Introduction Mepolizumab is a monoclonal antibody against IL-5 and is licensed for treatment of severe eosinophilic asthma (SEA). In clinical trials, most patients dependent on maintenance oral prednisolone (mOCS) were able to reduce or stop… read more here.

Keywords: treatment; one year; asthma; mocs ... See more keywords